Drug Profile
Research programme: TNF-alpha converting enzyme inhibitors - GlaxoSmithKline
Latest Information Update: 20 Mar 2007
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Small molecules
- Mechanism of Action Tumour necrosis factor-alpha convertase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 17 May 2002 Preclinical trials in Inflammation in USA (PO)